Main Article Content

Ainur Elliana Sohaimi Nur Syazwani Jamhuri Ismail Ibrahim Hotimah Masdan Salim

Abstract

Multiple myeloma (MM) is a hematological malignancy commonly associated with bone pain, hypercalcemia, and renal failure. However, its presentation can occasionally mimic other medical conditions, which may delay diagnosis. This case report describes a patient who was initially diagnosed and treated for heart failure but was later found to have MM, highlighting the importance of considering MM in the differential diagnosis of heart failure.


A 56-year-old lady presented with recurrent episodes of shortness of breath, orthopnea, paroxysmal nocturnal dypsnea and bilateral lower limb swelling which she had been treated for decompensated heart failure with optimal therapy. She denied any family history of cardiovascular disease personal history of underlying medical condition and was a nonsmoker. This patient was diagnosed with multiple myeloma and probability of concomitant cardiac amyloidosis and commenced on bortezomib, thalidomide and dexamethasone (VTD) regime and standard optimal therapy of heart failure but her condition deteriorated. After a few days of starting chemotherapy, patient demised despite all the resuscitative effort. Multiple myeloma is common hematological malignancy with its distinct clinical features of “CRAB”, however, more attention and alertness should also be exercised by clinicians as to be able to diagnose it early.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sohaimi, A. E. ., Jamhuri, N. S. ., Ibrahim, I. ., & Salim, H. M. . (2024). Atypical Presentation of Multiple Myeloma: From Heart Failure to Multiple Myeloma. Medical and Health Science Journal, 8(02), 57–63. https://doi.org/10.33086/mhsj.v8i02.6068
Section
Articles
Multiple myeloma, cardiac amyloidosis, systemic amyloidosis, heart failure, AL amyloidosis

References

Castaneda O, Baz R. Multiple Myeloma Genomics - A Concise Review. Acta Med Acad. 2019;48(1):57-67. doi:10.5644/ama2006-124.242

Xu J, Wang M, Shen Y, et al. Effects of amyloid light-chain amyloidosis on clinical characteristics and prognosis in multiple myeloma: A single-center retrospective study. Cancer Manag Res. 2021;13:1343-1356. doi:10.2147/CMAR.S287922

Kirichenko YY, Ilgisonis IS, Nakhodnova ES, et al. Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma—Diagnostic Difficulties. Front Cardiovasc Med. 2022;9(June):1-7. doi:10.3389/fcvm.2022.862409

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5

Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848-860. doi:10.1002/ajh.25819

Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. doi:10.1093/eurheartj/ehab072

Ríos-Tamayo R, Krsnik I, Gómez-Bueno M, et al. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor. Life. 2023;13(7):1-11. doi:10.3390/life13071518

Ainur Elliana Sohaimi, Department of Internal Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Malaysia

Nur Syazwani Jamhuri, Department of Internal Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Malaysia

Ismail Ibrahim, Department of Internal Medicine, Kulliyyah of Medicine, International Islamic University Malaysia, Malaysia

Hotimah Masdan Salim, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Nahdlatul Ulama Surabaya, Indonesia